title: Therapy of NMO spectrum disorders.
abstract: Neuromyelitis optica (NMO) is an autoimmune demyelinating condition of the central nervous system often associated with aquaporin-4 (AQP4) autoantibodies manifesting as severe optic neuritis and long segment myelitis with tendency to relapse. Seronegative patients and who do not meet the NMO criteria are classified as having NMO Spectrum Disorder (NMOSD), but are treated identically to clinically definite NMO. Acute relapse is treated with intravenous methylprednisolone for 5 days with or without subsequent treatment with plasma exchange (PE). This must be followed by oral steroid to prevent rebound worsening and further relapse. For relapse prevention, immunosuppressive agents that have been found to be effective are azathioprine, rituximab, mycophenolate mofetil, methotrexate, and mitoxantrone; although none of which have been validated in randomized, controlled trial. Some patients do relapse with monotherapy, and switching to more effective agent or use of combination therapy is beneficial in such situation. There is no consensus about the duration of preventive therapy, but generally 2-3 years of relapse-free period is considered the minimum, taking into account the risks of long-term toxicity of these agents.
authors.affiliation: Department of Neurology, Bangur Institute of Neurosciences, Kolkata, India.
authors.forename: Atanu
authors.initials: A
authors.lastname: Biswas
authors.affiliation: Department of Neurology, Vivekananda Institute of Medical Sciences, Kolkata, West Bengal, India.
authors.forename: Arabinda
authors.initials: A
authors.lastname: Mukherjee
keywords: Aquaporin-4; drug therapy; immunosuppression; neuromyelitis optica